Cover Image
市場調查報告書

Amakem NV - 產品平台分析

Amakem NV - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 283214
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Amakem NV - 產品平台分析 Amakem NV - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 25 Pages
簡介

Amakem NV是專精於眼科的製藥公司,正在開發為了眼睛健康的治療法。產品有青光眼和慢性阻塞性肺病治療藥等,為了開發各種眼科疾病治療藥而活用侷限性的藥物作用平台。

本報告提供Amakem NV的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Amakem NV的基本資料

Amakem NV概要

  • 主要資訊
  • 企業資料

Amakem NV:R&D概要

  • 主要的治療範圍

Amakem NV:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Amakem NV:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Amakem NV:藥物簡介

  • AMA-0076
  • AMA-0247
  • AMA-0428
  • AMA-0526
  • Drugs to Inhibit Kinase for Inflammatory Bowel Diseases

Amakem NV:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Amakem NV:最近的開發平台趨勢

Amakem NV:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06882CDB

Summary

Global Markets Direct's, 'Amakem NV - Product Pipeline Review - 2015', provides an overview of the Amakem NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amakem NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Amakem NV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Amakem NV's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Amakem NV's pipeline products

Reasons to buy

  • Evaluate Amakem NV's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Amakem NV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Amakem NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Amakem NV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amakem NV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Amakem NV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Amakem NV Snapshot
    • Amakem NV Overview
    • Key Information
    • Key Facts
  • Amakem NV - Research and Development Overview
    • Key Therapeutic Areas
  • Amakem NV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Amakem NV - Pipeline Products Glance
    • Amakem NV - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Amakem NV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Amakem NV - Drug Profiles
    • AMA-0076
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMA-0247
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMA-0428
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMA-0526
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kinase for Inflammatory Bowel Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Amakem NV - Pipeline Analysis
    • Amakem NV - Pipeline Products by Target
    • Amakem NV - Pipeline Products by Route of Administration
    • Amakem NV - Pipeline Products by Molecule Type
    • Amakem NV - Pipeline Products by Mechanism of Action
  • Amakem NV - Recent Pipeline Updates
  • Amakem NV - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Amakem NV, Key Information
  • Amakem NV, Key Facts
  • Amakem NV - Pipeline by Indication, 2015
  • Amakem NV - Pipeline by Stage of Development, 2015
  • Amakem NV - Monotherapy Products in Pipeline, 2015
  • Amakem NV - Phase II, 2015
  • Amakem NV - Preclinical, 2015
  • Amakem NV - Discovery, 2015
  • Amakem NV - Pipeline by Target, 2015
  • Amakem NV - Pipeline by Route of Administration, 2015
  • Amakem NV - Pipeline by Molecule Type, 2015
  • Amakem NV - Pipeline Products by Mechanism of Action, 2015
  • Amakem NV - Recent Pipeline Updates, 2015

List of Figures

  • Amakem NV - Pipeline by Top 10 Indication, 2015
  • Amakem NV - Pipeline by Stage of Development, 2015
  • Amakem NV - Monotherapy Products in Pipeline, 2015
  • Amakem NV - Pipeline by Top 10 Target, 2015
  • Amakem NV - Pipeline by Top 10 Route of Administration, 2015
  • Amakem NV - Pipeline by Top 10 Molecule Type, 2015
  • Amakem NV - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top